Summit Therapeutics Inc. Common Stock (SMMT)

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

265

Website

www.smmttx.com/

Fundamentals

1-day range

$13.52$14.02

Market cap

$10.80B

P/E (trailing)

—

P/E (forward)

-11.64

EPS (trailing)

$-1.12

Dividend yield

—

Beta

-1.61

Avg. volume

4.95M

Forecasts

13 analyst ratings

Summit Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.80BP/E —
  $12.07$29.23
• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.81BP/E —
  $112.9$260.19
• ABVX

  Abivax SA American Depositary Shares

  $113.41

  ▼ 0.78%
  Market cap $11.19BP/E —
  $60.45$139
• PRAX

  Praxis Precision Medicines Inc. Common Stock

  $344.95

  ▼ 6.23%
  Market cap $10.32BP/E —
  $37.19$392.7
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $10.13BP/E —
  $35.22$88.31
• MDGL

  Madrigal Pharmaceuticals Inc. Common Stock

  $534.12

  ▼ 1.76%
  Market cap $11.79BP/E —
  $393.61$615
• ELAN

  Elanco Animal Health Incorporated Common Stock

  $24.12

  ▼ 1.51%
  Market cap $12.09BP/E —
  $17.11$27.98

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
  benzinga · 8/26/2026
• HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral
  Benzinga · 8/18/2026
• Leerink Partners Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $13
  Benzinga · 8/12/2026
• Summit Therapeutics Expands Its Clinical Development Program For Ivonescimab Into Urothelial Carcinoma An Orbladder Cancer, With The Initiation Of The Global, Multi-Regional Phase II/III HARMONi-GU1 Trial
  Benzinga · 8/5/2026
• Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
  Benzinga · 8/4/2026
• Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches
  SeekingAlpha · 7/31/2026

• Zanganeh Mahkam · June 12, 2026 · Buy

  3.81M @ $13.12
• Robert W. Duggan · June 12, 2026 · Buy

  3.81M @ $13.12
• Manmeet Singh Soni · June 4, 2026 · Buy

  25.0K @ $14.46
• Zanganeh Mahkam · June 4, 2026 · Buy

  100.0K @ $14.6
• Robert W. Duggan · June 4, 2026 · Buy

  100.0K @ $14.6

Institutional Ownership

March 31, 2026

Total shares held

116.32M

Total value held

$2.04B

Institutional holders

221